Tacrolimus

Strong CYP3A inhibitor that may increase tacrolimus concentrations and risk of serious adverse reactions including neurotoxicity and QT prolongation.

Mifepristone increases tacrolimus exposure; concomitant use is contraindicated due to narrow therapeutic range.

Increased tacrolimus concentrations via CYP3A inhibition; avoid concomitant use.

Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.

Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.

Immunosuppressant that increases serum potassium, raising risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, monitor serum potassium.

Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.

Immunosuppressive drug with risk of added immunosuppression. Concomitant use with XELJANZ/XELJANZ XR is not recommended.

May increase the rate of tacrolimus release and increase risk of serious adverse reactions including neurotoxicity and QT prolongation.

Risk of hyperkalemia may be increased when amiloride HCl is administered concomitantly. Use with caution and frequent monitoring of serum potassium.

Amlodipine may increase systemic exposure of tacrolimus. Frequent monitoring of trough blood levels and dose adjustment recommended.

Amlodipine may increase systemic exposure of tacrolimus. Frequent monitoring of trough blood levels and dose adjustment recommended.

Amlodipine may increase systemic exposure of tacrolimus. Frequent monitoring of trough blood levels and dose adjustment recommended.

Strong CYP3A Inhibitors 3 : Protease inhibitors (e.g, nelfinavir, telaprevir, boceprevir, ritonavir), azole antifungals (e.g., voriconazole, posaconazole, itraconazole, ketoconazole), antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone, letermovir, Schisandra sphenanthera extracts May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation). Boceprevir: In a single-dose study in 12 subjects, co-administration of tacrolimus (0.5 mg single dose) with boceprevir (800 mg three times daily for 11 days) increased tacrolimus C max by 9.9-fold and AUC by 17-fold compared to tacrolimus alone [see Drug Interactions (7.2)] .

May decrease tacrolimus whole blood trough concentrations and increase risk of rejection. Increase tacrolimus dose and monitor concentrations.

May increase tacrolimus whole blood trough concentrations and increase risk of serious adverse reactions including neurotoxicity and QT prolongation. Reduce tacrolimus dose and adjust based on monitoring.

Strong CYP3A Inhibitors 3 : Protease inhibitors (e.g, nelfinavir, telaprevir, boceprevir, ritonavir), azole antifungals (e.g., voriconazole, posaconazole, itraconazole, ketoconazole), antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone, letermovir, Schisandra sphenanthera extracts May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation).

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., erythromycin, fluconazole), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions (5.6, 5.11, 5.12)].

May potentiate renal dysfunction; close monitoring of renal function recommended during concomitant use.

Danazol raises plasma levels of tacrolimus, leading to increased renal toxicity. Monitoring and dose adjustments may be needed.

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., erythromycin, fluconazole), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions (5.6, 5.11, 5.12)].

Risk of nephrotoxicity and deterioration of renal function due to decreased creatinine clearance. Requires careful benefit-risk assessment and renal function monitoring.

Immunosuppressant can produce nephrotoxicity and decreased creatinine clearance, increasing risk of renal function deterioration with fenofibric acid. Monitor renal function and use lowest effective dosage.

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., erythromycin, fluconazole), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions (5.6, 5.11, 5.12)].

Concomitant use should be avoided due to additive nephrotoxicity and renal impairment risk.

Associated with myelosuppression or nephrotoxicity; coadministration should be considered only if potential benefits outweigh risks.

Mild or Moderate CYP3A Inhibitors, such as: antibiotics (e.g., erythromycin), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole, azole antifungals (e.g., clotrimazole, fluconazole, isavuconazole), imatinib, nilotinib, letermovir May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions (5.6 , 5.9 , 5.10) ].

Mild or Moderate CYP3A Inhibitors, such as: antibiotics (e.g., erythromycin), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole, azole antifungals (e.g., clotrimazole, fluconazole, isavuconazole), imatinib, nilotinib, letermovir May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions (5.6 , 5.9 , 5.10) ].

Strong CYP3A Inhibitors 3 : Protease inhibitors (e.g, nelfinavir, telaprevir, boceprevir, ritonavir), azole antifungals (e.g., voriconazole, posaconazole, itraconazole, ketoconazole), antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone, letermovir, Schisandra sphenanthera extracts May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation).

Strong CYP3A Inhibitors 3 : Protease inhibitors (e.g, nelfinavir, telaprevir, boceprevir, ritonavir), azole antifungals (e.g., voriconazole, posaconazole, itraconazole, ketoconazole), antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone, letermovir, Schisandra sphenanthera extracts May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation). Ketoconazole: In a study of 6 normal volunteers, a significant increase in tacrolimus oral bioavailability (14 ± 5% vs. 30 ± 8%) was observed with concomitant ketoconazole administration (200 mg).

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., erythromycin, fluconazole), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions (5.6, 5.11, 5.12)].

Increase tacrolimus dose and monitor tacrolimus whole blood trough concentrations [see Dosage and Administration ( 2.2 , 2.6 ) and Clinical Pharmacology (12.3 ) ] Strong CYP3A Inhibitors : Protease inhibitors (e.g, nelfinavir, telaprevir, boceprevir, ritonavir), azole antifungals (e.g., voriconazole, posaconazole, itraconazole, ketoconazole), antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone,letermovir, Schisandra sphenanthera extracts May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation).A rapid, sharp rise in tacrolimus levels may occur early, despite an immediate reduction of tacrolimus dose [see Warnings and Precautions ( 5.6 , 5.11 , 5.12 )] Reduce tacrolimus dose (for voriconazole and posaconazole, give one-third of the original dose) and adjust dose based on tacrolimus whole blood trough concentrations [see Dosage and Administration ( 2.2 , 2.6 ) and Clinical Phamacology ( 12.3 )].

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., erythromycin, fluconazole), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions ( 5.6 , 5.11 , 5.12 )] Monitor tacrolimus whole blood trough concentrations and reduce tacrolimus dose if needed [see Dosage and Administration ( 2.2 , 2.6 ) and Clinical Pharmacology ( 12.3 )] Other drugs, such as: Magnesium and aluminum hydroxide antacids Metoclopramide May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions ( 5.6 , 5.11 , 5.12 )] Monitor tacrolimus whole blood trough concentrations and reduce tacrolimus dose if needed [see Dosage and Administration ( 2.2 , 2.6 ) and Clinical Pharmacology ( 12.3 )] Mild or Moderate CYP3A Inducers Methylprednisolone, prednisone May decrease tacrolimus concentrations Monitor tacrolimus whole blood trough concentrations and adjust tacrolimus dose if needed [see Dosage and Administration ( 2.2 , 2.6 )] Caspofungin May decrease tacrolimus whole blood trough concentrations Monitor tacrolimus whole blood trough concentrations and adjust tacrolimus dose if needed [see Dosage and Administration ( 2.2 , 2.6 )] .

Other drugs, such as: Magnesium and aluminum hydroxide antacids Metoclopramide May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions (5.6, 5.11, 5.12)].

May increase tacrolimus whole blood trough concentrations and increase risk of serious adverse reactions including neurotoxicity and QT prolongation. Reduce tacrolimus dose and adjust based on monitoring.

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., erythromycin, fluconazole), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions (5.6, 5.11, 5.12)].

Nicardipine may elevate plasma tacrolimus levels through inhibition of hepatic microsomal enzymes including CYP3A4. Plasma concentrations should be closely monitored and dose adjusted accordingly.

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., erythromycin, fluconazole), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions (5.6, 5.11, 5.12)].

Mild or Moderate CYP3A Inhibitors, such as: antibiotics (e.g., erythromycin), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole, azole antifungals (e.g., clotrimazole, fluconazole, isavuconazole), imatinib, nilotinib, letermovir May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions (5.6 , 5.9 , 5.10) ].

Amlodipine increases exposure to tacrolimus, requiring monitoring.

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., erythromycin, fluconazole), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions (5.6, 5.11, 5.12)].

May decrease tacrolimus whole blood trough concentrations and increase risk of rejection. Increase tacrolimus dose and monitor concentrations.

May decrease tacrolimus whole blood trough concentrations and increase risk of rejection. Increase tacrolimus dose and monitor concentrations.

Strong CYP3A Inhibitors 3 : Protease inhibitors (e.g, nelfinavir, telaprevir, boceprevir, ritonavir), azole antifungals (e.g., voriconazole, posaconazole, itraconazole, ketoconazole), antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone, letermovir, Schisandra sphenanthera extracts May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation). Reduce tacrolimus dose (for voriconazole and posaconazole, give one-third of the original dose) and adjust dose based on tacrolimus whole blood trough concentrations [see Dosage and Administration (2.2, 2.6) and Clinical Pharmacology (12.3)] . Posaconazole (see complete prescribing information for Noxafil) : Repeat oral administration of posaconazole (400 mg twice daily for 7 days) increased tacrolimus (0.05 mg/kg single dose) C max and AUC in healthy subjects by an average of 2-fold (90% CI: 2.01, 2.42) and 4.5-fold (90% CI 4.03, 5.19), respectively [ s ee Drug Interactions (7.2)] .

Posaconazole significantly increases tacrolimus Cmax and AUC. Reduce tacrolimus dose to approximately one-third and monitor whole blood trough concentrations frequently.

Concurrent use increases risk of severe and potentially fatal hyperkalemia, particularly in presence of other hyperkalemia risk factors.

Increases risk of severe and potentially fatal hyperkalemia, particularly in presence of other risk factors. Avoid use if possible.

CYP3A substrate with narrow therapeutic range. Dose adjustment may be required as ranolazine increases plasma concentrations.

May decrease tacrolimus whole blood trough concentrations and increase risk of rejection. Increase tacrolimus dose and monitor concentrations.

May decrease tacrolimus whole blood trough concentrations and increase risk of rejection. Increase tacrolimus dose and monitor concentrations.

Strong CYP3A Inhibitors 3 : Protease inhibitors (e.g, nelfinavir, telaprevir, boceprevir, ritonavir), azole antifungals (e.g., voriconazole, posaconazole, itraconazole, ketoconazole), antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone, letermovir, Schisandra sphenanthera extracts May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation).

May increase tacrolimus whole blood trough concentrations and increase risk of serious adverse reactions including neurotoxicity and QT prolongation. Reduce tacrolimus dose and adjust based on monitoring.

Tacrolimus increases hyperkalemia risk; avoid use due to potassium content or monitor serum potassium concentrations.

Increased risk of severe and potentially fatal hyperkalemia when potassium chloride solution is administered.

May decrease tacrolimus whole blood trough concentrations and increase risk of rejection. Increase tacrolimus dose and monitor concentrations.

Strong CYP3A Inhibitors 3 : Protease inhibitors (e.g, nelfinavir, telaprevir, boceprevir, ritonavir), azole antifungals (e.g., voriconazole, posaconazole, itraconazole, ketoconazole), antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone, letermovir, Schisandra sphenanthera extracts May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation). Telaprevir: In a single-dose study in 9 healthy volunteers, co-administration of tacrolimus (0.5 mg single dose) with telaprevir (750 mg three times daily for 13 days) increased the tacrolimus dose-normalized C max by 9.3-fold and AUC by 70-fold compared to tacrolimus alone [see Drug Interactions (7.2)] .

Tigecycline may increase serum trough concentrations of tacrolimus, leading to risk of toxicity. Monitor serum concentrations during treatment.

Strong CYP3A Inhibitors 3 : Protease inhibitors (e.g, nelfinavir, telaprevir, boceprevir, ritonavir), azole antifungals (e.g., voriconazole, posaconazole, itraconazole, ketoconazole), antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone, letermovir, Schisandra sphenanthera extracts May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation).

Associated with myelosuppression or nephrotoxicity. Coadministration should be considered only if potential benefits outweigh risks.

Co-administration with valganciclovir should be considered only if potential benefits outweigh risks due to potential for higher toxicity from myelosuppression or nephrotoxicity.

Strong CYP3A Inhibitors 3 : Protease inhibitors (e.g, nelfinavir, telaprevir, boceprevir, ritonavir), azole antifungals (e.g., voriconazole, posaconazole, itraconazole, ketoconazole), antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone, letermovir, Schisandra sphenanthera extracts May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation). Reduce tacrolimus dose (for voriconazole and posaconazole, give one-third of the original dose) and adjust dose based on tacrolimus whole blood trough concentrations [see Dosage and Administration (2.2, 2.6) and Clinical Pharmacology (12.3)] . Voriconazole (see complete prescribing information for VFEND) : Repeat oral dose administration of voriconazole (400 mg every 12 hours for one day, then 200 mg every 12 hours for 6 days) increased tacrolimus (0.1 mg/kg single dose) C max and AUCτ in healthy subjects by an average of 2-fold (90% CI: 1.9, 2.5) and 3-fold (90% CI: 2.7, 3.8), respectively [see Drug Interactions (7.2)] .

P-glycoprotein inhibitor that increases afatinib exposure. Reduce GILOTRIF dose by 10 mg per day if not tolerated.

Risk of hyperkalemia may be increased when used concomitantly with amiloride HCl. Requires caution and frequent monitoring of serum potassium.

Amlodipine may increase systemic exposure of tacrolimus. Frequent monitoring of trough blood levels and dose adjustment recommended.

Amlodipine may increase systemic exposure of tacrolimus. Frequent monitoring of trough blood levels and dose adjustment recommended.

CYP3A4 inhibitors; concomitant administration in patients with widespread and/or erythrodermic disease should be done with caution.

Therapeutic drug monitoring and dose reduction for tacrolimus should be considered when co-administered with cannabidiol.

Concomitant use with caspofungin acetate requires monitoring. Standard monitoring of tacrolimus trough whole blood concentrations and appropriate dosage adjustments are recommended.

CYP3A4 inhibitor; concomitant administration in patients with widespread and/or erythrodermic disease should be done with caution.

Deferasirox may induce CYP3A4 resulting in decreased tacrolimus concentration. Monitor for reduced effectiveness.

Mild or moderate CYP3A inhibitor calcium channel blocker that may affect tacrolimus concentrations. Monitor tacrolimus whole blood trough concentrations.

Monitor and adjust dosage as needed. Dronedarone is a CYP3A and P-gp inhibitor that increases exposure of narrow therapeutic index substrates.

Esomeprazole magnesium may increase serum levels of tacrolimus, requiring monitoring.

Esomeprazole magnesium may increase serum levels of tacrolimus, requiring monitoring.

Felodipine may increase blood concentration of tacrolimus; tacrolimus blood concentration should be monitored and dose may need adjustment.

May increase plasma phenytoin concentrations after fosphenytoin conversion.

Associated with myelosuppression or nephrotoxicity. Coadministration considered only if benefits outweigh risks.

Increase in tacrolimus exposure. Monitor drug concentrations and adjust dose as needed.

Immunosuppressant may increase risk of hyperkalemia when used with CLINIMIX E due to its potassium content; administer with caution.

Methylene blue inhibits CYP3A4/5 metabolism. Tacrolimus has narrow therapeutic index; clinical relevance unknown but concurrent use requires caution.

CYP3A4 substrate whose plasma levels may increase with concomitant metronidazole use. Monitor plasma concentrations.

Effects of Other Drugs/Substances on ENVARSUS XR a, d a ENVARSUS XR dosage adjustment recommendation based on observed effect of co-administered drug on tacrolimus exposures [see Clinical Pharmacology (12.3) ] , literature reports of altered tacrolimus exposures, or the other drug’s known CYP3A inhibitor/inducer status b High dose or double strength grapefruit juice is a strong CYP3A inhibitor; low dose or single strength grapefruit juice is a moderate CYP3A inhibitor c Strong CYP3A inhibitor/inducer, based on reported effect on exposures to immediate-release tacrolimus along with supporting in vitro CYP3A inhibitor/inducer data, or based on drug-drug interaction studies with midazolam (sensitive CYP3A probe substrate) d A drug interaction study with voriconazole was conducted for ENVARSUS XR [see Clinical Pharmacology (12.3) ] .

Can increase MPA exposure after crossover from cyclosporine to tacrolimus. Monitor for MPA-related adverse reactions and adjust MMF or MPA dose as needed.

Can increase MPA exposure after crossover from cyclosporine to tacrolimus. Monitor for MPA-related adverse reactions and adjust dose as needed.

Amlodipine increases exposure to tacrolimus.

Omeprazole and sodium bicarbonate may increase serum levels of tacrolimus. Monitor for potential dose adjustments.

Sensitive CYP3A substrate with narrow therapeutic index. Dose may need reduction when coadministered with palbociclib.

QT interval prolonging drug. Coadministration with VANFLYTA may further increase incidence of QT prolongation. More frequent ECG monitoring recommended.

Sevelamer carbonate may reduce bioavailability of tacrolimus, which could have clinically significant effect on safety or efficacy. Consider separation of administration timing.

Reduction in bioavailability may have clinically significant effect on safety or efficacy; consider separation of administration timing.

Sevelamer may reduce bioavailability of tacrolimus, which has clinically significant effects on safety or efficacy. Consider separation of administration timing.

Avoid use due to potassium content increasing risk of hyperkalemia. If unavoidable, monitor serum potassium concentrations.

LOKELMA decreases systemic exposure to tacrolimus by elevating gastric pH. Separate administration by at least 2 hours.

Amlodipine may increase systemic exposure of tacrolimus. Monitor accordingly.

Tinidazole may increase tacrolimus levels. Monitor for signs of calcineurin-inhibitor associated toxicities during co-administration.

Amlodipine may increase the systemic exposure of tacrolimus. Frequent monitoring of trough blood levels is recommended and adjust dose when appropriate.

Mild or moderate CYP3A inhibitor calcium channel blocker that may affect tacrolimus concentrations. Monitor tacrolimus whole blood trough concentrations.

Amlodipine may increase systemic exposure of tacrolimus. Frequent monitoring of trough blood levels and dose adjustment recommended.

Co-administration resulted in no significant alteration in steady state pharmacokinetics of either drug. No dosage adjustment needed.

Co-administration with micafungin did not alter pharmacokinetics of either drug.